in this issue
Regions :: Western Europe :: Switzerland
Lonza to Develop, Manufacture U.S. Biopharma Firm’s Antibody Drug Conjugate
7:36 AM MDT | September 27, 2012 | Deepti Ramesh
Lonza says that biopharmaceutical company Intellect Neurosciences (New York) has awarded the future development and manufacture of the antibody-drug conjugate Conjumab-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s Conjumab-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease, Lonza says. Intellect is engaged in the discovery and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee